0000000001037372

AUTHOR

Blanca Ferrer

showing 4 related works from this author

Amplification of human β-glucoronidase gene for appraising the accuracy of negative SARS-CoV-2 RT-PCR results in upper respiratory tract specimens

2020

Real-time reverse transcription polymerase-chain reaction (RT-PCR) is the mainstay of Covid-19 diagnosis. False-negative RT-PCR results may hamper clinical management of patients and hinder the adoption of epidemiological measures to control the pandemic. The current study was aimed at assessing whether amplification of β-glucoronidase (GUSB) gene would help estimate the accuracy of SARS-CoV-2 RT-PCR negative results in upper respiratory tract (URT) specimens. URT specimens that tested negative by SARS-CoV-2 RT-PCR displayed higher GUSB RT-PCR cycle thresholds (CT) (P=0.070) than those testing positive (median, 30.7; range, 27.0-40.0, and median 29.7; range 25.5-36.8, respectively), this re…

AdultMalemedicine.medical_specialtyAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory SystemSensitivity and SpecificityGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineHumansIn patient030212 general & internal medicineRespiratory systemChildLetter to the EditorGeneAgedGlucuronidaseAged 80 and overReceiver operating characteristicClinical Laboratory TechniquesReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2business.industryCurve analysisCOVID-19Middle AgedVirologyReverse transcriptaseGlucuronidaseTrue negativeInfectious Diseasesmedicine.anatomical_structureReal-time polymerase chain reactionChild PreschoolRNA ViralFemale030211 gastroenterology & hepatologybusinessRespiratory tract
researchProduct

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review

2021

Patients with postransplant lymphoproliferative disease (PTLD) who are refractory to rituximab-based regimens have extremely poor prognosis. Data is lacking in the setting of solid organ transplantation (SOT)-related PTLD treated with chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, limited information is available on the influence of concomitant immunosuppressive drugs on CAR-T function. Here, we describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion. This report also reviews the limited published data in the setting of SOT-related PTLD treated…

Oncologymedicine.medical_specialtymedicine.medical_treatmentImmunotherapy AdoptiveGeneral Biochemistry Genetics and Molecular BiologyRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansKidneyReceptors Chimeric Antigenbusiness.industryImmunosuppressionOrgan TransplantationGeneral MedicineLymphoproliferative DisordersTransplant RecipientsChimeric antigen receptorDiscontinuationsurgical procedures operativemedicine.anatomical_structureConcomitantRituximabLymphoproliferative diseasebusinessmedicine.drugCurrent Research in Translational Medicine
researchProduct

Assessing the potential association between SARS-CoV-2 RNA load in the respiratory tract and COVID-19 mortality.

2020

Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐XI

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory System03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumans030212 general & internal medicineAgedbusiness.industrySARS-CoV-2RNACOVID-19Middle AgedViral LoadVirologyInfectious Diseasesmedicine.anatomical_structureHospital admissionRNA Viral030211 gastroenterology & hepatologyFemalebusinessBiomarkersRespiratory tractJournal of medical virology
researchProduct

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

2023

AbstractThe long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3–6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection a…

OncologySARS-CoV-2VaccinationCOVID-19Malalties transmissiblesVacunacióHematologyHematologia
researchProduct